Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome

Medical Mycology

Volumn 52, Issue 7, 2014, Pages 699-705

  Van De Peppel, Robert J ^a   Dekkers, Olaf M ^a   Von Dem Borne, Peter A ^a   De Boer, Mark G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AML; antifungal stewardship; chemoprophylaxis; Invasive aspergillosis; MDS; resistance; risk factors

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; IMMUNOLOGIC FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; CANCER RECURRENCE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; STEM CELL TRANSPLANTATION; UNIVARIATE ANALYSIS; COMPLICATION; INVASIVE PULMONARY ASPERGILLOSIS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENT DISEASE; STATISTICAL MODEL;

COHORT STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; INVASIVE PULMONARY ASPERGILLOSIS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 84911434352     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myu036     Document Type: Conference Paper

References (23)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Inf Dis 2001; 32: 358-366.
2. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neu-tropenia. NJM 2007; 356: 348-359.
3. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Anti-fungal Therapy (PATH) Alliance registry. Clin Inf Dis 2009; 48: 265-273.
4. Mirkov I, Stosic-Grujicic S, Kataranovski M. Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection. Imm Res 2012; 52: 120-126.
5. Baddley JW. Clinical risk factors for invasive aspergillosis. Med Myco 2011; 49 (Suppl 1): S7-S12.
6. Li L, Wang J, Zhang W, Yang J, Chen L, Lv S. Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients. Scand J Inf Dis 2012; 44: 100-107.
7. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
8. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Mul-tivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984; 53: 411-419.
9. Kullberg BJ OLA, Janssen J, Meis J, Natsch S, Verweij PE. SWAB Guidelines for the Management of Invasive Fungal Infections. 2009, www.swab.nl/guidelines, accessed November 2013.
10. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Inf Dis 2011; 52: 427-431.
11. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46: 709-718.
12. Camps SM, Rijs AJ, Klaassen CH et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50: 2674-2680.
13. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis-has the principle been proven? New En. J Med 2007; 356: 409-411.
14. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Inf Dis 2011; 17: 1846-1854.
15. Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Mi-crobiol Inf 2013; 19: 745-751.
16. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Blood Marrow Transplant 2009; 15: 1143-1238.
17. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Inf Dis 2008; 46: 1813-1821.
18. Vehreschild JJ, Ruping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myel-ogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chem 2010; 65: 1466-1471.
19. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-1601.
20. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicobiol Chemo 2010; 165: 410-416.
21. Egger SS, Meier S, Leu C et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 2010; 45: 1197-1203.
22. Marks DI, Pagliuca A, Kibbler CC et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Brit J Haematol 2011; 155: 318-327.
23. Bowyer P, Moore CB, Rautemaa R, Denning DW, Richardson MD. Azole antifungal resistance today: focus on Aspergillus. Curr Inf Dis Rep 2011; 13: 485-491.